Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS other · 2026-03-03

Clinical Trial Update: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating retatrutide (LY3437943) for maintenance of weight reduction in obesity is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Retatrutide (retatrutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING